Latest news ...

Some of our recent news articles.

 
03
July
2019
03rd July 2019
 

Catalent Completes Acquisition Of Gene Therapy Leader Paragon

Catalent Completes Acquisition Of Gene Therapy Leader Paragon Bioservices, Inc. For $1.2 Billion

 
Read the full story »
 
 
03
July
2019
03rd July 2019
 

Catalent snaps up Novavax production sites and 100 employees in $18M deal

Another deal has been struck in the rapidly evolving market for gene therapy manufacturing. Just two months after Catalent jumped big time into the gene therapy realm, it is adding a couple of small vaccine production sites and a 100 employees to its operation.  

 
Read the full story »
 
 
06
July
2018
06th July 2018
 

Catalent Signs Agreement To Acquire Juniper Pharmaceuticals, Inc.

Catalent, Inc. the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division.
 
Read the full story »
 
 
20
July
2017
20th July 2017
 

Pfizer Partners With Catalent For The Manufacture Of Advil® Liqui-Gels® Minis

Somerset, N.J., – July 12, 2017 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that following a successful 20-year collaboration on the development and manufacture of Advil® Liqui-Gels® (ibuprofen), it has entered into an exclusive long-term supply agreement to produce the next generation of Pfizer Inc.’s leading over-the-counter (OTC) pain relief product with the launch of new Advil Liqui-Gels Minis, using Catalent’s innovative softgel platform OptiGel™ Mini technology.
 
Read the full story »
 
 
13
June
2017
13th June 2017
 

Catalent Completes Accucaps Acquisition To Expand Softgel Development And Manufacturing Capabilities And Capacity

SOMERSET, N.J. – February 16, 2017 — Catalent, Inc. (Catalent) (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the acquisition of Accucaps Industries Limited (Accucaps), the Canada-based developer and manufacturer of Over-the-Counter (OTC), high-potency and conventional pharmaceutical softgels. Financial details of the transaction have not been disclosed.
 
Read the full story »
 
 
31
January
2016
31st January 2016
 

Catalent continues to scout acquisitions and licensing in 2016

Catalent will pursue strategic acquisitions and licensing in 2016, said VP Marketing & Strategy Elliott Berger, noting growth areas include complex delivery technologies and specialised logistics.
 
Read the full story »
 
 
 
 
 
 
 
 
 

About Us

SURIMS is the new name for Actex Pharma Services which was a consultancy established in 2003, supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own supplier on-boarding and supplier management activities. Further information on our software services please contact Tel: +353 87 294 0436 or email info@pharmaservicesdirectory.com

 
 
 

Get in Touch

The Pharmaceutical Services Directory
info@pharmaservicesdirectory.com.

 
 

© 2019 Actex Pharma Services | All Rights Reserved.